Illimis Therapeutics: Valuation, Funding & Investors
Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for challenging cancers, Alzheimer's, and immune diseases. Leveraging its proprietary GAIA platform, the company aims to advance its drug development pipeline through strategic global partnerships, including collaborations with industry leaders like Lilly Catalyze360-ExploR&D.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 652
Latest Estimated Valuation
- Total Amount Raised
- $42M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $42M
- Latest Funding Round
- Series B
Company Momentum
PositiveIllimis Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Illimis Therapeutics had 29 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Illimis Therapeutics had 652 followers as of November 16, 2026. The number of followers increased by 6 (0.93%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 14, 2025 | Series B | $42.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Woori Venture Partners | Series B |
| DSC Investment | Series B |
| Korea Development Bank | Series B |
| Aju IB Investment | Series B |
| Quad Asset Management | Series B |
| Company K Partners | Series B |
| GS Ventures | Series B |
| Dayli Partners | Series B |
Similar Companies
A snapshot of private companies similar to Illimis Therapeutics, helping you discover and navigate related company profiles.








